Hepatitis C Information Central


Discover the latest news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information

News, Updates and Commentary

Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.

HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Report Assesses Blame in Hepatitis Cases
Health care workers at a Las Vegas endoscopy clinic linked to more than 80 cases of hepatitis C routinely mishandled injection equipment and medication vials and often failed to perform basic hand hygiene, according to a report from the Centers for

New treatment for hepatitis C
Oklahoma City: Researchers at the University of Oklahoma Health Sciences Center have found a new use for an old drug. Their findings appear online in the American Journal of Gastroenterology. The drug, Fluvastatin, has been approved since 1993 by the


UPDATES AND COMMENTARY RSS Feed

What You Must Know About Alcoholic Hepatitis
This much-needed synopsis of alcoholic hepatitis reminds us that you don't need to be a heavy drinker to suffer from this condition. Looking over the causes, risk factors and complications of alcoholic hepatitis will motivate anyone with liver concerns to...

15 Tips for Managing Interferon-Ribavirin Side Effects
Finding new ways to manage the side effects of Hepatitis C combination therapy adds to a person’s likelihood of conquering the virus....

New Mexico Offers Free Hepatitis C Hotline
Finally being recognized as the widespread, public health problem that it is, the New Mexico Department of Health has taken a giant step forward to help people with Hepatitis C. By launching a new, toll-free phone number, locals concerned about...

New Warnings Placed On Rebetron Hepatitis Therapy

PHILADELPHIA, PA -- Feb. 18, 1999 -- After just six months on the market, revised safety information tells doctors and patients to be even more cautious in the use of combination therapy to treat hepatitis C.

A black box warning in the revised prescribing information for Schering-Plough’s Rebetron(TM) warns that patients and their partners must use two forms of contraception because of the risk of birth defects or loss of a pregnancy from combination therapy.

Even if only one partner is taking Rebetron, both members of the couple need to use adequate contraception during therapy and for six months after the end of treatment.

Rebetron is a combination of Rebetol(R) (ribavirin, USP) Capsules and Intron(R) A (interferon alfa-2b, recombinant) Injection. It is the ribavirin component that is blamed for the risks to the fetus.

The United States Food and Drug Administration recently approved Rebetron combination therapy for patients with hepatitis C who had never been treated before. Previously, only people who had failed a previous treatment could receive Rebetron. But at the same time as it allowed wider use, the FDA increased the warnings to reflect the danger of the combination therapy during pregnancy. Ever since Rebetron was first approved, Schering-Plough has maintained a registry to track people on the therapy who become pregnant.

Dr. Enrique Molina, a hepatologist and assistant professor of clinical medicine at the Center for Liver Diseases, University of Miami, FL., says no patients with pregnancy-related complications from Rebetron treatment have been referred to his practice yet. However, he feels physicians need to counsel patients carefully before prescribing Rebetron.

"If a patient is not willing to practice strict contraception, that's certainly a contraindication for ribavirin. It makes a bigger difference for younger patients than for older ones," he said. "Many of our patients are 40 or 50 and already practising contraception so it's not a big issue for them, but for those that are younger, it's definitely an important point for physicians to stress."

table Of Contents

Hepatitis Central

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 17 May 2008